%0 Practice Guideline
%T Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis.
%A Rovin BH
%A Ayoub IM
%A Chan TM
%A Liu ZH
%A Mejía-Vilet JM
%A Balk EM
%A Gordon CE
%A Adam G
%A Tonelli MA
%A Cheung M
%A Earley A
%A Floege J
%J Kidney Int
%V 105
%N 1
%D 2024 Jan
%M 38182299
%F 18.998
%R 10.1016/j.kint.2023.09.001
%X The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Glomerular Diseases was published in 2021. Since then, the pace of drug development for glomerular diseases has accelerated, due in large part to rapidly accumulating insights into disease pathogenesis from genetic and molecular studies of afflicted patients. To keep the Glomerular Diseases Guideline as current as possible, KDIGO made a commitment to the nephrology community to provide periodic updates, based on new developments for each disease. After the 2021 guideline was published, two novel drugs received regulatory approval for the management of lupus nephritis, leading to the first KDIGO guideline update. Herein, an executive summary of the most important guideline changes from the Lupus Nephritis chapter is provided as a quick reference.